The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
Rana R. McKay(University of California San Diego), Toni K. Choueiri(Harvard University), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Daniel Castellano(Universidad Complutense de Madrid), J. Connor Wells(Queen's University), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Sumanta K. Pal(City of Hope), Dylan J. Martini(Dana-Farber Cancer Institute), Xiao X. Wei(Dana-Farber Cancer Institute), Stephanie A. Wankowicz(Vanderbilt University), Sabina Signoretti(Brigham and Women's Hospital), Lauren C. Harshman(Dana-Farber Cancer Institute), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Jae‐Lyun Lee(Ulsan College), Abdallah Flaifel(Brigham and Women's Hospital), Wanling Xie(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), André P. Fay(Hospital São Lucas da PUCRS), Raphael Brandão Moreira(Dana-Farber Cancer Institute), Joann Hsu(City of Hope), Fabio A.B. Schutz(Beneficência Portuguesa de São Paulo), Guillermo de Velasco(Dana-Farber Cancer Institute), Dominick Bossé(Dana-Farber Cancer Institute), Daniel Y.C. Heng(University of Calgary), Darren R. Feldman(Memorial Sloan Kettering Cancer Center)
Cited by 136
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k